Compare Amylx Pharmaceuticals Inc (AMLX) vs Banco Santander SA (SAN) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amylx Pharmaceuticals Inc vs Banco Santander SA — how do they compare? Amylx Pharmaceuticals Inc trades at $17.77 (market cap $1.98B), while Banco Santander SA trades at $13.75 (market cap $197.91B). The key difference: Banco Santander SA is far larger — about 100× Amylx Pharmaceuticals Inc's market cap, and Banco Santander SA pays a 2.01% dividend while Amylx Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMLX | SAN | |
|---|---|---|
Market Cap | $1.98B | $197.91B |
Sector | Health | Financials |
52-Week High | $18.70 | $14.37 |
52-Week Low | $7.64 | $8.31 |
Enterprise Value | $1.70B | — |
Dividend Yield | — | 2.01% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMLX trades at $17.77, down 3.32% today, with a bullish technical signal from moving averages and strong analyst support. The company is in a pivotal phase with key Phase 3 data for avexitide expected in Q3 2026, targeting a potential 2027 launch. Financially, it shows significant losses with negative ROE and ROA, but cash flow from financing activities provides runway. Recent news highlights clinical progress and conference presentations, alongside ongoing class action settlement discussions.
The outlook hinges on successful clinical trial outcomes, particularly avexitide's Phase 3 readout, which could drive substantial upside toward the $30.50 consensus price target. However, high execution risk, persistent cash burn, and legal overhangs pose threats to near-term stability. Investor sentiment remains cautiously optimistic given the 90.9% buy rating from analysts, but the stock is speculative until profitability milestones are achieved.
Banco Santander (SAN) trades at $13.87, up 0.58% today, with a bullish technical signal from moving averages. The company reported $14.10B net income for 2025 with a 23.49% margin, though recent quarterly EPS results missed expectations. Analyst consensus is 64% buy, supported by news of Santander becoming Spain's most valuable company and its AI-driven efficiency initiatives.
Outlook is cautiously optimistic with strong profitability and strategic acquisitions, but risks include consecutive EPS misses, a significant net cash outflow trend, and regulatory scrutiny in Spain. The stock's valuation appears reasonable with a P/E of 13.78, offering potential upside if operational improvements materialize.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amylx Pharmaceuticals Inc
Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.
Read more on AMLX →About Banco Santander SA
Santander's focus is on retail and commercial banking. Latin America is geographically the largest operation, with Brazil by far the largest. Its continental European business is still mainly Iberian. Santander's U.K. presence is the result of the acquisition of building society Abbey. In the U.S., Santander operates a vehicle finance business and a regional bank focused on the Northeastern states.
Read more on SAN →
